J. Goldman & CO LP Adicet Bio, Inc. Transaction History

J. Goldman & CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$13.43 - $18.74 $766,772 - $1.07 Million	57,094 New	57,094 $812,000
Q2 2022 Aug 15, 2022	SELL	$10.26 - $20.81 $201,609 - $408,916	-19,650 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.53 - $19.97 $10,123 - $17,533	878 Added 4.68%	19,650 $392,000
Q4 2021 Feb 14, 2022	BUY	$7.37 - $17.49 $138,349 - $328,322	18,772 New	18,772 $328,000
Q2 2021 Aug 16, 2021	SELL	$9.19 - $15.93 $882,662 - $1.53 Million	-96,046 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.12 - $17.17 $62,951 - $89,180	-5,194 Reduced 5.13%	96,046 $1.26 Million
Q4 2020 Feb 16, 2021	BUY	$10.36 - $14.77 $1.05 Million - $1.5 Million	101,240 New	101,240 $1.42 Million

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $36M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.